BioXcel Therapeutics
Price & Volume
Stats
See more52W Range | $1.06-$8.08 |
Market Cap | $28.6M |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $642,000 |
Revenue Growth (YoY) | -30.1% |
Gross Profit (12 Mos) | $478,000 |
Diluted EPS | -$5.73 |
News
See moreYahoo Finance • 4 days ago
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
Yahoo Finance • last month
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
Yahoo Finance • 4 months ago
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
Yahoo Finance • 5 months ago
BioXcel Therapeutics GAAP EPS of -$2.18 misses by $0.84
About
CEO | Dr. Vimal D. Mehta Ph.D. |
CFO | Mr. Richard I. Steinhart MBA |
Address | 555 Long Wharf Drive, New Haven, CT, United States, 06511 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 29 |
